Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Zelos Therapeutics, Inc. is a private biopharmaceutical company that is developing breakthrough discoveries in Parathyroid Hormone (PTH) research. Product programs include the development of a next-generation PTH analogue, Ostabolin-CÔ, for the treatment of osteoporosis that is currently in Phase II trials and a PTH agonist for the topical treatment of psoriasis, also in clinical development. The Company has a collaboration with Nektar Therapeutics for the development of a pulmonary formulation of Ostabolin-CÔ for the treatment of osteoporosis. Zelos maintains administrative offices in Waltham, Mass. and research facilities in Ottawa, Ontario. ( www.zelostherapeutics.com )
Zelos Therapeutics Inc.
One Tower Bridge 100 Front Street, Suite 1325
West Conshohocken, Pennsylvania 19428
USA
Tel: (610) 825-4547
Fax: (610) 825-3936